NYSE
CTLT

Catalent Inc

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Catalent Inc Stock Price

Vitals

Today's Low:
$48.205
Today's High:
$49.48
Open Price:
$48.44
52W Low:
$31.45
52W High:
$115.335
Prev. Close:
$49.02
Volume:
1521943

Company Statistics

Market Cap.:
$6.92 billion
Book Value:
27.291
Revenue TTM:
$4.76 billion
Operating Margin TTM:
14.72%
Gross Profit TTM:
$1.64 billion
Profit Margin:
8.62%
Return on Assets TTM:
4.1%
Return on Equity TTM:
8.73%

Company Profile

Catalent Inc had its IPO on 2014-07-31 under the ticker symbol CTLT.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Catalent Inc has a staff strength of 19,000 employees.

Stock update

Shares of Catalent Inc opened at $48.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $48.21 - $49.48, and closed at $48.29.

This is a -1.49% slip from the previous day's closing price.

A total volume of 1,521,943 shares were traded at the close of the day’s session.

In the last one week, shares of Catalent Inc have slipped by -3.8%.

Catalent Inc's Key Ratios

Catalent Inc has a market cap of $6.92 billion, indicating a price to book ratio of 1.7713 and a price to sales ratio of 1.6504.

In the last 12-months Catalent Inc’s revenue was $4.76 billion with a gross profit of $1.64 billion and an EBITDA of $1.10 billion. The EBITDA ratio measures Catalent Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Catalent Inc’s operating margin was 14.72% while its return on assets stood at 4.1% with a return of equity of 8.73%.

In Q4, Catalent Inc’s quarterly earnings growth was a negative -15.4% while revenue growth was a negative 5.6%.

Catalent Inc’s PE and PEG Ratio

Forward PE
13.1926
Trailing PE
16.5647
PEG
1.1774

Its diluted EPS in the last 12-months stands at $2.32 per share while it has a forward price to earnings multiple of 13.1926 and a PEG multiple of 1.1774. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Catalent Inc’s profitability.

Catalent Inc stock is trading at a EV to sales ratio of 2.5279 and a EV to EBITDA ratio of 11.8419. Its price to sales ratio in the trailing 12-months stood at 1.6504.

Catalent Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$11.15 billion
Total Liabilities
$1.53 billion
Operating Cash Flow
$-608000000.00
Capital Expenditure
$168 million
Dividend Payout Ratio
0%

Catalent Inc ended 2024 with $11.15 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $11.15 billion while shareholder equity stood at $4.91 billion.

Catalent Inc ended 2024 with $221.00 million in deferred long-term liabilities, $1.53 billion in other current liabilities, 2000000.00 in common stock, $619.00 million in retained earnings and $3.22 billion in goodwill. Its cash balance stood at $442.00 million and cash and short-term investments were $470.00 million. The company’s total short-term debt was $644,000,000 while long-term debt stood at $4.22 billion.

Catalent Inc’s total current assets stands at $2.92 billion while long-term investments were $0 and short-term investments were $28.00 million. Its net receivables were $1.45 billion compared to accounts payable of $367.00 million and inventory worth $841.00 million.

In 2024, Catalent Inc's operating cash flow was $-608000000.00 while its capital expenditure stood at $168 million.

Comparatively, Catalent Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$48.29
52-Week High
$115.335
52-Week Low
$31.45
Analyst Target Price
$53.25

Catalent Inc stock is currently trading at $48.29 per share. It touched a 52-week high of $115.335 and a 52-week low of $115.335. Analysts tracking the stock have a 12-month average target price of $53.25.

Its 50-day moving average was $46.65 and 200-day moving average was $50.39 The short ratio stood at 0.91 indicating a short percent outstanding of 0%.

Around 36.6% of the company’s stock are held by insiders while 10582.9% are held by institutions.

Frequently Asked Questions About Catalent Inc

The stock symbol (also called stock or share ticker) of Catalent Inc is CTLT

The IPO of Catalent Inc took place on 2014-07-31

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$2631.5
-32.3
-1.21%
$124.83
-3.22
-2.51%
Copart Inc (CPRT)
$44.22
-0.78
-1.73%
$45.41
-0.36
-0.79%
$0.17
0.02
+12.67%
Symphony Limited (SYMPHONY)
$886.65
-17.65
-1.95%
$0.17
0
+1.35%
$11.03
-0.56
-4.83%
$59.72
-0.62
-1.03%
$275.4
-17.05
-5.83%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Address

14 Schoolhouse Road, Somerset, NJ, United States, 08873